Cardiovascular Adverse Event Risk Following a COPD Exacerbation
In the first 30 days following an exacerbation of chronic obstructive pulmonary disease, there is an increased risk of cardiovascular adverse events.
In the first 30 days following an exacerbation of chronic obstructive pulmonary disease, there is an increased risk of cardiovascular adverse events.
Researchers conducted a retrospective analysis of patients with COPD who were hospitalized and mechanically ventilated.
In patients with type 2 asthma, dupilumab was associated with significantly lower annualized outpatient asthma exacerbation rates and lower total number of days using systemic corticosteroids.
Expired or previously used and sterilized N95 respirators can be used when new N95 respirators are unavailable during the COVID-19 pandemic.
The Theraflu Home FluTest, a novel rapid influenza diagnostic test, demonstrated good sensitivity and specificity for both influenza A and B viruses.
Matthew Robbins, MD, author of “COVID-19 and headache: a primer for trainees,” details how care has changed for patients with chronic headaches in the midst of the COVID-19 pandemic.
Tobacco smoke exposure inhibited the therapeutic benefit of the cystic fibrosis transmembrane conductance regulator modulators in pediatric patients.
Compared with white patients, black patients with screen-detected cancers had a lower calculated lung cancer risk, despite having a significantly higher mean 6-year lung cancer risk.
In patients who were hospitalized with severe coronavirus disease, treatment with lopinavir-ritonavir did not provide a substantial benefit beyond standard care.
In a post hoc analysis of the LIBERTY ASTHMA QUEST study, researchers found that dupilumab may reduce exacerbations in patients with allergic bronchopulmonary aspergillosis.